 There has not been a reduction in the revenues at ResVet. They've continued to see a growth in sales. And longer term, I do wonder that the part of the science that we don't know yet, which is what is it going to be like for people to be taking GLP-1 drugs chronically over a very long period of time? We don't really have data yet. So I think that investors are right to be nervous.